News

MEDTRONIC, symplicity renal denervation catheter

One of the exciting new frontiers for interventional cardiology is the use of renal denervation therapy to treat pharmacologically uncontrolled hypertension. It is estimated there are more...

Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted...

T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical outcomes. In 26 patients who presented with chest pain and underwent cardiac...

July 15, 2013 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental new drug application (sNDA)...

Clinical Study Aspirin Duke Medicine Blood Test Platelet Functioning Testing

Aspirin has been widely used for more than 50 years as a common, inexpensive blood thinner for patients with heart disease and stroke, but doctors have little understanding of how it works and why...

cath lab, SYNTAX, SCAI

The year 2013 has brought us several important clinical trials that have changed the way interventional cardiologists approach and treat patients with stable coronary artery disease. These trials...

St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal...

Boston Scientific Vessix Renal Denervation System Hypertension Therapies

Boston Scientific Corporation reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with...

June 3, 2013 — St. Jude Medical Inc. announced the company’s EnligHTN multi-electrode renal denervation system provides a safe, rapid and sustained reduction in blood pressure...

Kona Medical announced three and six month results from the WAVE I study, a first-in-man study evaluating the safety and efficacy of Kona Medical’s Surround Sound Renal Denervation System for...

Can high blood pressure be safely reduced and controlled by “disconnecting” nerves in the kidneys? That is a question that a new ...

University of Maryland Medical Center Genetic-Testing Program Cardiac Stent

Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...

Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device for...

Merck FDA Approval Liptruzet

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin) tablets for the treatment...

The U.S. Food and Drug Administration approved Kcentra (prothrombin complex concentrate, human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major...

UK Blood Clots Teststing Wafarin Self Monitoring

A simple self-monitoring test could reduce the risk of stroke by half in thousands of people in the United Kingdom who currently take warfarin to prevent blood clots. Better access to self-...

Population Health Management Medical Therapy Angioplasty Coronary Artery Disease

The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major...

Cardiosonic Inc. announced the completion of the first phase of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and...

Accumetrics Inc. VerifyNow P2Y12 Test Bleeding Ischemic Events

Accumetrics Inc. announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for...

The U.S. Food and Drug Administration (FDA) issued a second complete response letter regarding a supplemental new drug application (sNDA) for Xarelto (rivaroxaban) for the reduction of the risk of...